Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-024-04696-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Ming Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Drug Interactions, Cytochrome P-450 CYP3A Inhibitors, Models, Biological, Cytochrome P-450 CYP2C19 Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Bristol-Myers Squibb.
Abstract (Originalsprache)
PURPOSE: A physiologically based pharmacokinetic (PBPK) model for fedratinib was updated and revalidated to bridge a gap between the observed drug-drug interaction (DDI) of a single sub-efficacious dose in healthy participants and the potential DDI in patients with cancer at steady state. The study aimed to establish an appropriate dose for fedratinib in patients coadministered with dual CYP3A4 and CYP2C19 inhibitors, providing quantitative evidence to inform dosing guidance. METHODS: The original minimal PBPK model was developed using Simcyp® Simulator v17. The model was updated by substituting a single distribution rate (Qsac) with 2 separate rates (CLin/CLout) and transitioning to v20. Model parameter updates were further informed with 3 clinical studies, and 3 more studies served as independent validation data. The validated model was applied to simulate potential DDIs between fedratinib and a known dual inhibitor of CYP3A4 and CYP2C19 (fluconazole). RESULTS: Coadministration of fedratinib with fluconazole in patients was predicted to increase fedratinib exposure by < 2-fold in all simulated scenarios. For patients with cancer receiving the approved dose of fedratinib 400 mg once daily along with fluconazole 200 mg daily, the model predicted an approximate 50% increase in fedratinib exposure at steady state. CONCLUSIONS: The updated PBPK model improved description of the observed pharmacokinetics and predicted a low risk of clinically significant DDIs between fedratinib and fluconazole. The quantitative evidence serves as a primary foundation for providing dose guidance in clinical practice for the coadministration of fedratinib with dual CYP3A4 and CYP2C19 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bristol Myers Squibb, Princeton, NJ, USA.
- Bristol Myers Squibb, Princeton, NJ, USA. Yizhe.chen@bms.com.
ORCID-Profile: Yizhe Chen, Ken Ogasawara, Lu Gaohua
Förderung
- Bristol-Myers Squibb
Zitieren
APA
Chang, M., Chen, Y., Ogasawara, K., Schmidt, B. J., & Gaohua, L. (2024). Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04696-y
Vancouver
Chang M, Chen Y, Ogasawara K, Schmidt BJ, Gaohua L. Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04696-y
BibTeX
@article{Chang2024,
author = {Chang, Ming and Chen, Yizhe and Ogasawara, Ken and Schmidt, Brian James and Gaohua, Lu},
title = {Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-024-04696-y}
}
EUVIMED